Article
A polymorphic enhancer near GREM1 influences bowel cancer risk through differential CDX2 and TCF7L2 binding.
Cell reports - 21 Aug 2014
Lewis Annabelle, Freeman-Mills Luke, de la Calle-Mustienes Elisa, Giráldez-Pérez Rosa María, Davis Hayley, Jaeger Emma, Becker Martin, Hubner Nina C, Nguyen Luan N, Zeron-Medina Jorge, Bond Gareth, Stunnenberg Hendrik G, Carvajal Jaime J, Gomez-Skarmeta Jose Luis, Leedham Simon, Tomlinson Ian
Abstract excerpt
A rare germline duplication upstream of the bone morphogenetic protein antagonist GREM1 causes a Mendelian-dominant predisposition to colorectal cancer (CRC). The underlying disease mechanism is strong, ectopic GREM1 overexpression in the intestinal epithelium. Here, we confirm that a common GREM1 polymorphism, rs16969681, is also associated with CRC susceptibility, conferring ∼20% differential risk in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
